WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001029218) NUCLEAR MATRIX PROTEINS, POLYNUCLEOTIDE SEQUENCES ENCODING THEM, AND THEIR USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/029218    International Application No.:    PCT/US2000/028498
Publication Date: 26.04.2001 International Filing Date: 16.10.2000
Chapter 2 Demand Filed:    15.05.2001    
IPC:
C07K 14/47 (2006.01)
Applicants: UNIVERSITY OF PITTSBURGH [US/US]; 200 Gardner Steel Conference Center, Thackeray & O'Hara Streets, Pittsburgh, PA 15260 (US) (For All Designated States Except US).
GETZENBERG, Robert, H. [US/US]; (US) (For US Only)
Inventors: GETZENBERG, Robert, H.; (US)
Agent: BENT, Stephen, A.; Foley & Lardner, 3000 K. Street, N.W., Suite 500, Washington, DC 20007-5109 (US)
Priority Data:
09/418,839 15.10.1999 US
Title (EN) NUCLEAR MATRIX PROTEINS, POLYNUCLEOTIDE SEQUENCES ENCODING THEM, AND THEIR USE
(FR) PROTEINES DE MATRICE NUCLEAIRE, SEQUENCES POLYNUCLEOTIDIQUES CODANT CES PROTEINES ET UTILISATION DE CES PROTEINES
Abstract: front page image
(EN)Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue, particularly prostate tissue, are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
(FR)L'invention concerne des protéines de matrice nucléaire (PMN) qui sont caractérisées par une expression définie dans le tissu, en particulier dans le tissu de la prostate. Ces PMN sont des marqueurs utiles pour le diagnostic et la surveillance du degré de malignité d'une cellule, et pour le traitement des maladies à prolifération cellulaire associées aux PMN. L'invention concerne également des polypeptides sensiblement purifiés et des séquences nucléotidiques codant pour ces PMN.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)